B.Riley Downgrades Ambrx Biopharma (AMAM) to Neutral

B.Riley analyst Yuan Zhi downgraded Ambrx Biopharma (NASDAQ: AMAM) from Buy to Neutral with a price target of $28.00 (from $26.00).

For an analyst ratings summary and ratings history on Ambrx Biopharma click here. For more ratings news on Ambrx Biopharma click here.

Shares of Ambrx Biopharma closed at $13.63 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Va Tech Wabag Ltd. (VATW:IN) PT Raised to INR2,410 at ICICI Securities
• GMR Airports Infrastructure (GMRI:IN) PT Raised to INR99 at ICICI Securities